X

Get our occasional Market Report emails

sent straight to your inbox

There’s no charge for this.

Getting latest data loading
X

Request a Call to Trade

In addition to the daily Research emails, I would also like to receive the Accendo Markets Weekly Newsletter and occasional Market Report emails highlighting various trading opportunities.
When you enter your telephone number, we may call or message you occasionally with trading opportunities. You can opt out at any time
Home / Support and Resistance / GlaxoSmithKline (GSK.L) 18-02-20

This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.

GlaxoSmithKline (GSK.L) 18-02-20

Will GlaxoSmithKline (GSK.L) shares break below the 1650p support, or return to highs of 1846p (+11%)?

 

  • Currently close to the 1650p support at 1657.6p (at time of writing).
  • This has been identified for ostensibly strong support level. Traders should consider whetehr they think it will hold up again.
  • Will the price bounce again to recent highs at 1846p? (+11%).
  • Technical traders should consider potential news and developments. Check our website and the press for updates in future.
  • Shares -10% from 12-month highs; +10% from 12 month lows.

Latest News

08:30:  Liberum Capital reiterates its hold rating on GlaxoSmithKline (GSK) and reduced the target price to 1840p (from 1930p).

13 Feb:  Societe Generale reiterates its buy rating on GlaxoSmithKline (GSK) and reduced the target price to 2240p (from 2300p).

13 Feb:  HSBC reiterates its buy rating on GlaxoSmithKline (GSK) and reduced the target price to 2050p (from 2110p).

11 Feb:  UBS reiterates its buy rating on GlaxoSmithKline (GSK) and reduced the target price to 1900p (from 1950p).

11 Feb:  JP Morgan Cazenove reiterates its neutral rating on GlaxoSmithKline (GSK) and reduced the target price to 1750p (from 1900p).

10 Feb:  Deutsche Bank reiterates its hold rating on GlaxoSmithKline (GSK) and reduced the target price to 1600p (from 1650p).

07 Feb:  Barclays Capital reiterates its underweight rating on GlaxoSmithKline (GSK) and reduced the target price to 1550p (from 1650p).

Source: Bloomberg, Reuters, Alpha Terminal, FT, DJ Newswires

 

Click to enlarge

This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.


Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when spread betting and/or trading CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
.